Compare Eli Lilly And Co (LLY) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Redwire Corporation — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Redwire Corporation trades at $9.58 (market cap $2.44B). The key difference: Eli Lilly And Co is far larger — about 426.2× Redwire Corporation's market cap, and Eli Lilly And Co pays a 0.59% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Redwire Corporation for 18 Days on average.
| LLY | RDW | |
|---|---|---|
Market Cap | $1.04T | $2.44B |
Volume | 3,064,878 | 11,053,212 |
Sector | Health | Industrials |
52-Week High | $1.28K | $25.90 |
52-Week Low | $799.57 | $5.06 |
Typical Hold Time | 93 Days | 18 Days |
Enterprise Value | $1.09T | $1.97B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
RDW trades at $9.76, down 4.69% on the day, reflecting a bearish technical trend. The company reported a net loss of $226.55M in 2025, with a negative net margin of -57.26%, though revenue grew to $335.38M. Recent news highlights strategic partnerships, including a $981M Space Force contract and collaborations with Honda and Sophia Space on robotics and orbital data centers, signaling growth potential in the space infrastructure sector.
The outlook is mixed: strong analyst consensus (80% buy ratings) and a $14.88 price target suggest upside, but persistent losses, negative cash flow from operations, and dependence on SpaceX's success pose significant risks. Investors face high volatility amid speculative growth prospects in the evolving space economy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
